Our Life Sciences portfolio capacity creates flexible, cutting-edge research and lab environments within several of the nation’s top 10 leading life sciences markets, boasting a unique combination of world-class healthcare and academic institutions, top-tier talent, and investment capital.
As Philadelphia continues to lead the way with groundbreaking research and solidify its standing as one of the nation’s leading hubs for Life Sciences, Brandywine is committed to developing over 1.1 million square feet of Life Science lab and research space, all of which is shovel-ready for delivery by 2023.
Expected delivery time: 2Q2021
Stories: floors 2-9 to be converted to dedicated life sciences use
Standard floor plate: 27,000 SF
Use: fully functioning life science space appropriate for chemical and biological lab uses, with potential for lab incubator space
3025 JFK WEST
Expected delivery time: 1Q2023
Stories: 28 stories above grade with 2 additional levels below grade
Standard floor plate: 28,000 GSF
Use: optimized for lab space, or a combination of lab and office space
Keystone Opportunity Zone Incentive Site
3151 MARKET STREET
Expected delivery time: 2Q2023
Stories: 12-14 plus one level below grade parking
Standard floor plate: 34,200 GSF
Use: ground-up life science building with options for full floors of intensive chemical and biological lab use including the potential for GMP and vivarium functions, lower level parking and ground floor retail/active space and amenities
BULLETIN BUILDING (FULLY LEASED)
Expected delivery time: 4Q2020
Stories: 4 stories plus roof top space
Standard floor plate: 50,000 GSF
Use: fronting the new 1.3 acre park Drexel Square located across the street from 30th Street Station, the Bulletin Building is a mix of office and lab space for Spark Therapeutics, and introduces 10,000 SF of new retail space
3000 MARKET STREET (FULLY LEASED)
Expected delivery time: core completion 1Q2021
Stories: 2 plus one level below grade for parking
Standard floor plate: 30,000 SF
Use: life science building fully leased to Spark Therapeutics for intensive biological lab use
Expected delivery time: 4Q2022
Standard floor plate: 28,000 SF
Use: complete capability throughout the building, with options for all lab, all office, or a combination of these uses
Brandywine Realty Trust (NYSE: BDN) is one of the largest, publicly-traded, full-service, integrated real estate companies in the United States, with a core focus in the Philadelphia, PA, Washington, D.C., and Austin, TX markets. Organized as a real estate investment trust (REIT), we own, develop, lease and manage an urban, town center and transit-oriented portfolio.
Our purpose is to shape, connect and inspire the world around us through our expertise, the relationships we foster, the communities in which we live and work, and the history we build together. Our deep commitment to our communities was recognized by NAIOP when we were presented with the Developer of the Year Award—the highest honor in the commercial real estate industry.